Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Rewinding RX

Claya
Graded #268

Higher grade

vs+3.299999999999997
Rewinding RX
Graded #340

Lower grade

The verdict

Claya takes it — 62.8/100 to 59.5/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRewinding RX +3
42
45
Dose & formulationClaya +35
75
40
Clinical oversightRewinding RX +3
82
85
Labs & monitoringEven
53
53
FulfillmentRewinding RX +20
67
87
Contract termsEven
61
61
Claya · left barRewinding RX · right bar

The numbers

MetricClayaRewinding RX
WeighScore62.8/10059.5/100
GradeCC
Scorecard rank#268#340
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Rewinding RX

Graded #340 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer — uncommon transparency
  • MD-only physician network ('never a physician assistant or nurse')
  • All-50-state coverage with physician state-licensing matching
  • Corporate entity disclosed (Rewinding RX Ltd.)

Where it loses points

  • Pricing not shown — fully gated behind sign-up
  • Pharmacy partner not named (only generic 503A/503B references)
  • Medical director / clinical leadership not disclosed
  • Governing law, arbitration venue, and corporate address not disclosed
  • Tirzepatide not listed on the homepage (semaglutide only confirmed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard